Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allosteric modulator

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Allosteric modulator. Displaying page 1 of 1.
    EudraCT Number: 2013-001263-23 Sponsor Protocol Number: BP27832 Start Date*: 2014-03-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)
    Medical condition: Down Syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10044688 Trisomy 21 PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003912-23 Sponsor Protocol Number: ADX10059-202 Start Date*: 2006-10-26
    Sponsor Name:Addex Pharmaceuticals SA
    Full Title: A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 i...
    Medical condition: Dental anxiety
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003791-13 Sponsor Protocol Number: BP42992 Start Date*: 2022-01-11
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15...
    Medical condition: Dup15q Syndrome
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004850 10083952 Dup15q syndrome LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-001488-51 Sponsor Protocol Number: ADX10059-201 Start Date*: 2006-08-01
    Sponsor Name:Addex Pharmaceuticals S.A.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF THE MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ADX10059 IN THE ACUTE TREATMENT OF MIGRAINE
    Medical condition: Migraine with or without aura
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002106-36 Sponsor Protocol Number: JNJ-DEP Start Date*: 2016-01-11
    Sponsor Name:Clinirx Tangent Research
    Full Title: The effects of JNJ-39393406 on psychometric performance and residual depressive symptoms in 80 patients with unipolar or bipolar depression: a phase II exploratory add-on double blind placebo contr...
    Medical condition: Unipolar and bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    19.0 100000004873 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2008-005104-10 Sponsor Protocol Number: ADX10059-204 Start Date*: 2008-11-04
    Sponsor Name:Addex Pharma SA
    Full Title: A phase 2B, randomised, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the efficacy, mechanism of action, pharmacokinetics, safety and tolerability of the mGluR...
    Medical condition: Gastroesophageal Reflux Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005105-18 Sponsor Protocol Number: ADX10059-205 Start Date*: 2008-11-04
    Sponsor Name:Addex Pharma SA
    Full Title: A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multi-centre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric mod...
    Medical condition: Gastroesophagal Reflux Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) SE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005481-30 Sponsor Protocol Number: ADX10059-206 Start Date*: 2009-03-03
    Sponsor Name:Addex Pharma SA
    Full Title: A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multicentre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modu...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) FR (Ongoing) GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003221-29 Sponsor Protocol Number: XPF-008-201 Start Date*: 2020-03-12
    Sponsor Name:Xenon Pharmaceuticals Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Ex...
    Medical condition: Adult focal (partial onset) epilepsy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:38:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA